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ABSTRACT
Autoimmune diseases such as systemic lupus
erythematosus (SLE), rheumatoid arthritis,
multiple sclerosis, autoimmune hepatitis, and
inflammatory bowel disease have complex
pathogeneses and the courses of events
leading to these diseases are not well
understood. The immune surveillance is a
delicate balance between self and foreign as
well as between tolerance and immune
response. Exposure to certain environmental
factors may impair this equilibrium, leading to
autoimmune diseases, cancer, and the so-called
‘‘lifestyle diseases’’ such as atherosclerosis, heart
attack, stroke, and obesity, among others. These
external stimuli may also alter the epigenetic
status quo and may trigger autoimmune
diseases such as SLE in genetically susceptible
individuals. This review aims to highlight the
role of epigenetic (dys-)regulation in the
pathogenesis of SLE.
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INTRODUCTION
One interesting hypothesis concerning
autoimmune diseases is that environmental
effects on immune responses could be
mediated by alterations in the epigenetic
profile. Indeed, there is evidence that
environmental factors may be the reason for
the high discordance rate for autoimmune
diseases in identical twins [1–4]. Advances in
molecular genetics have illustrated that
genomes are not a static entity for the
deposition of genetic information. These
findings imply dynamic response to external
stimuli and a high genomic plasticity that is
affected by epigenetic gene regulation. This
kind of gene regulation relies on inducible
and/or heritable patterns of gene expression,
which are not based on changes of the genomic
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DNA sequence. Major mechanisms include
DNA methylation, histone modification, non-
coding RNA expression, gene imprinting and
chromatin remodeling. Although in neither of
these cases is gene expression modified by
changes in the base sequence, these
mechanisms interact with each other in a
complex manner to regulate the expression
and silencing of genes.
As epigenetic gene regulation is a new and
highly promising research field (in autoimmune
diseases), this article reviews the role of
epigenetic regulation in systemic lupus
erythematosus (SLE). This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
WHAT IS EPIGENETICS?
Although known before, the word ‘‘epigenetics’’
was introduced in modern science in 1942 by
Conrad Hal Waddington, a British
developmental biologist [5]. The concept of
epigenetics is defined as the study of
regulatory mechanisms that account for
(potentially) heritable and reversible patterns
in gene expression without affecting the
nucleotide sequence of the genome. As the
Greek prefix ‘‘ ‘‘ (epi) means ‘‘upon, over, on
top of’’, the ‘‘epigenome’’ is thought to be an
additional, secondary informational level on
top of the genetic code. A classic example of
epigenetic regulation in mammals is the dosage
compensation by silencing of one X
chromosome in females. A condensed
chromatin configuration prevents expression
of genes on the silenced X chromosome, while
the other X chromosome in the same nucleus is
actively transcribed [6, 7]. It has been shown in
humans that the silencing of individual gene
loci by imprinting (in combination with micro
deletions and mutations) leads to
developmental abnormalities, known as
Beckwith–Wiedemann, Angelman and Prader–
Willi syndromes [8–10].
As the molecular basis of inheritance was
unknown at that time, the term was initially
used in an unspecific sense. This in conjunction
with the description of the DNA double-helix
structure by Watson and Crick, which
demonstrated its eminent role in inheritance
[11], ‘‘have cast a shadow over this discipline for
decades’’ [12]. The term was reintroduced no
more than four decades later, as studies on
chromatin structure had identified the
molecular basis of epigenetics.
The year 1974 marked the ‘‘birth-year’’ of
modern, molecular-based epigenetics. There,
Kornberg and colleagues published that
chromatin is ‘‘a repeating unit of histones and
DNA’’ [13]. These repetitive units were then
called ‘‘nucleosomes’’. However, it took until
1996 before two studies provided the first clear
connection between histone acetylation and
transcriptional regulation [14, 15] and it took
further 4 years before a functional link between
histone methylation and chromatin structure
could be established [16].
In transcription and DNA replication,
changes in the chromatin structure are
essential to overcome steric hindrances for
DNA binding factors [17–19]. These
fundamental alterations are called ‘‘chromatin
remodeling’’. Chromatin remodeling is,
amongst other things, based on post-
translational modifications of histones by
histone-modifying enzymes, which induce a
complex cascade of post-translational
modifications that can either activate or
repress transcription [20]. This has led to the
notion that defined patterns of histone
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modifications alter the structure of higher order
chromatin to recruit effector molecules [21].
The different combinations of these
modifications are thought to constitute a code,




Among the approximately 3 billion base pairs of
the mammalian genome, there are
20,000–30,000 protein-coding genes [22–24],
which need instructions for where and when
to be expressed or silenced. Only the accurate
interplay of these genes results in functioning
cells, organs and organisms. Like cancer and
other complex diseases, autoimmune diseases
seem to be the result of multistep processes in
which genetic predisposition and epigenetic
alterations interact and contribute to the
pathological changes of this susceptible
interplay.
Two major groups of cellular compounds are
affected by epigenetic changes: the genome and
the histones. Major mechanisms of epigenetic
gene regulation include DNA methylation,
histone modification, non-coding RNA
expression, gene imprinting, and chromatin
remodeling (Fig. 1). Mainly, three types of
epigenetic modifications of chromatin
transition are known: histone hypoacetylation,
methylation of lysine 9 of histone H3
[Me(Lys9)H3], and DNA methylation at CpG
dinucleotides. However, Me(Lys9)H3 is typically
not found on regulated genes. It is characteristic
for so-called constitutive heterochromatin,
whereas genes that are shut off are typically
localized in ‘facultative’ heterochromatin,
which is marked by tri-methylated lysine 27 on
histone H3 (H3K27me3).
Histones are subject to diverse post-
translational modifications including
acetylation, methylation, phosphorylation,
and ubiquitylation [21, 25, 26]. In 1996,
Taunton et al. [15] identified the first histone
deacetylase (HDAC), a human homolog of the
yeast transcriptional regulator Rpd3p. Since
that time, large and ancient families of HDACs
have been identified in yeast as well as in
mammals [27–29]. It is believed that HDACs
reverse the regulatory acetylation of histone
proteins and silence genes by stabilizing a
transcription-incompetent condition of
nucleosomes [27]. It has been demonstrated in
animal models that HDAC inhibitors are
therapeutic for several inflammatory diseases
[30], suggesting a potential therapeutic use of
these inhibitors in autoimmune diseases.
Fig. 1 Epigenetics and autoimmune disease. Five different
epigenetic mechanisms have been identiﬁed so far: histone
modiﬁcation, non-coding RNA expression, DNA
methylation, gene imprinting, and chromatin remodeling.
These mechanisms interact with each other in a complex
manner to regulate the expression and silencing of genes.
Environmental factors may be the reason for the (high)
discordance rate for autoimmune diseases in identical
twins. These environmental factors may alter the
epigenetic status quo and may trigger autoimmune diseases,
including systemic lupus erythematosus (SLE), rheumatoid
arthritis (RA), multiple sclerosis (MS), inﬂammatory
bowel disease, as well as autoimmune diabetes, thyroid
disease and hepatitis
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Methylation of lysine 9 of histone H3 is
catalyzed by the mammalian homolog of the
fruit fly suppressor of variegation 3–9
[Su(var)3–9], which is a histone lysine
methyltransferase that selectively methylates
histone H3 at this site [16]. This modification
generates a binding site for HP1 proteins, a
family of heterochromatic transcriptional
repressors that establish a repressed chromatin
state [31–33], which is also called ‘‘gene
silencing’’.
DNAmethylation patterns are established and
maintained by methyltransferases [34]. Any
deletion of these enzymes is lethal during
embryogenesis [35–37]. Methylated cytosines
within CpG dinucleotides are recognized by
methyl-CpG binding proteins that recruit
HDACs and thereby induce an inhibitory
chromatin configuration [38]. Histone and DNA
modifications arehighlydynamic, a property that
is crucial for the regulation and control of cellular
proliferation, differentiation and survival [39].
Moreover, they are substantial constituents of the
so-called ‘‘epigenetic code’’ [40].
In the last three decades, major advances
have been made in understanding the
interaction between DNA methylation, histone
modification, and gene expression. This
fundamental research demonstrated that the
interplay between the individual components is
highly complex and opened the new field of
epigenetics. In the last few years, it became
evident that epigenetic changes are not only
involved in cancer and developmental processes
but also play a significant role in the
etiopathology of autoimmune diseases.
EPIGENETIC CHANGES
IN AUTOIMMUNE DISEASES
The mechanisms underlying epigenetic changes
are of great importance to human autoimmune
diseases. However, they are poorly understood
(Fig. 2). Over the years, increasing evidence has
demonstrated the important role for aberrant
epigenetics in the pathogenesis of SLE [41].
A number of genes have been claimed to be
associated with susceptibility to anti-self
responses. Because of their considerable
heterogeneity, the immunoglobulin genes, the
T cell receptor genes and the major
histocompatibility complex (MHC) genes have
soon been suspected of playing a distinct role in
the pathology of SLE and other autoimmune
diseases. In the past few years, progress has been
made in identifying SLE susceptibility genes in
mice [42]. However, these models only try to
decipher the complex genetic background of
SLE, but not the comparably complex
environmental background of the disease. In
general, mice are housed under (standardized)
specific pathogen-free conditions and, thus, do
not fully resemble the human disease.
Interestingly, the data on several autoimmune
diseases (including SLE) disclose increasing
disease rates over the past few decades [43]. As
genetic determinants are unlikely to alter
disease rates within such short intervals, any
rapid change indicates an environmental
influence [43].
Since Holliday and Pugh proposed that
‘‘cytoplasmic components can have a powerful
or overriding influence on genomic activity’’ in
1975 [44], many investigations broadened our
understanding of epigenetic alterations in the
pathogenesis of various complex disorders,
including cancer and autoimmunity. One
important epigenetic mechanism is the
cytosine methylation/demethylation ‘‘switch’’
of regulatory DNA sequences. Highly
simplified, methylation inactivates
transcription, while hypomethylation
associated with the activation of genes [45–
47]. CpG dinucleotides are found at a lower
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frequency in the genome than would be
expected due to random distribution, a
phenomenon called ‘‘CG suppression’’. This
loss of CpGs has been explained by a
spontaneous deamination of methylated
cytosine residues [48]. In contrast, regions
with a higher CpG content are found in
approximately 40% of mammalian promoters
[49]. These accumulations are called ‘‘CpG
islands’’ [38, 50] and in most instances the
CpG sites of these CpG islands are
unmethylated if the genes are expressed.
Environmentally induced hypomethylation of
proinflammatory genes on the one hand and
hypermethylation of anti-inflammatory genes
on the other hand may have the effect that
genetically susceptible individuals come down
with an autoimmune disease.
HOW IS SLE INFLUENCED
BY EPIGENETIC CHANGES?
T cells from patients with active SLE have a 17%
decrease in genomic deoxymethylcytosine
content [51] and the inhibition of T cell DNA
methylation causes autoreactivity in vitro and a
SLE-like disease in vivo [51]. In murine models
of drug-induced lupus erythematosus, it has
been shown that mice receiving CD4? T cells
treated with demethylating agents, including
procainamide and hydralazine, develop a SLE-
like disease [52]. These drugs also inhibit T cell
Fig. 2 Possible roles of epigenetic alterations involved in
SLE pathogenesis. Genetic disposition in combination with
environmental factors can alter epigenetic marks, such
as DNA (de-)methylation, histone modiﬁcations and
transcriptional regulation by non-coding RNA. These
epigenetic modiﬁcations may lead to aberrant gene
expression proﬁles in (autoreactive) T cells that activate
proinﬂammatory and repress anti-inﬂammatory genes.
Aberrant and continuous expression of chemokines and
cytokines mobilizes autoreactive B cells, which may trigger
and aggravate SLE. SLE systemic lupus erythematosus
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DNA methylation and induce autoreactivity in
cloned T cell lines [53, 54]. CD4? T cells treated
with DNA methylation inhibitor 5-azacytidine
become autoreactive and respond to self-class II
MHC without the addition of exogenous
antigen [55]. In lupus-prone MRL/lpr mice,
defective DNA methylation and CD70
overexpression in CD4? T cells could be
detected [56].
It is well known that an exposure to
ultraviolet light can trigger lupus flares [57,
58]. Moreover, brief exposures of T cells to
ultraviolet light induce DNA hypomethylation
and T cell autoreactivity [59], which supports an
association between T cell DNA
hypomethylation and autoimmunity [60].
Lymphocyte function-associated antigen-1
(LFA1) is a heterodimer consisting of the
integrin alpha L (ITGAL) and the beta 2 chain
(ITGB2), which is expressed on all leukocytes. In
T cells from SLE, patients’ sequences flanking
the ITGAL gene promoter region were
demethylated, suggesting a mechanism for
LFA-1 overexpression on an autoreactive
subset of T cells [51]. Indeed, overexpression
of LFA-1 [60, 61] and CD70 (TNFSF7) [62, 63],
which, in turn, induces autoantibody synthesis
in B cells [64], is thought to be involved in T cell
autoreactivity in SLE. Additional studies have
confirmed that DNA hypomethylation and
histone hyperacetylation of CD11a and CD70
promoter regions contribute to their
overexpression in SLE CD4? T cells [51, 65,
66]. Hypermethylation of MHC class II
transactivator (MHC2TA) and downregulation
of human leukocyte antigen (HLA)-DR and
MHC2TA could also be observed [67].
Different blood cell populations of SLE
patients are characterized by a global loss of
DNA methylation [68]. For instance, persistent
hypomethylation of interferon genes and
interferon-regulated genes can be found in
CD4? T cells [69], CD19? B cells, CD14?
monocytes [70], and neutrophils [71] of
patients with SLE. This process is associated
with defects in extracellular-signal-regulated
kinases (ERK) pathway signaling and
consequent downregulation of the
methyltransferase DNMT 1 [72]. These studies
indicate that T cells hypomethylated by
treatment with DNA methyltransferase
inhibitors or ERK pathway inhibitors are
sufficient to induce a SLE-like disease [73].
Recently, it could be shown that female but
not male mice with an inducible ERK defect
developed SLE-like symptoms in a transgenic
mouse model, demonstrating ERK-dependent
female predisposition for SLE [74]. Gorelik et al.
[75] traced the SLE ERK pathway defect to
impaired protein kinase C delta (PKCd)
phosphorylation. Additionally identified
demethylation targets in SLE are genes
involved in inflammation (CD40LG) [74, 76],
cytokine pathway (IL-4 [77, 78], IL-6 [77, 79], IL-
10 [80], IL-13 [80]) and IL1R2 [81], respectively)
and cell lysis (perforin [82, 83]), which all can
increase inflammation by stimulating the
immune system.
Another example concerns the
overexpression of the transcription regulatory
factor cAMP-responsive element modulator
alpha (CREMa) in T cells of patients with SLE
and lupus-prone MRL/lpr mice. It binds to the
CRE site in the promoter region of genes and
contributes to epigenetic remodeling through
the recruitment of DNA methyltransferase
DNMT3A [84]. Then, DNMT3A mediates CpG
hypomethylation, remodeling the CD8 cluster
[85] and silencing of IL2 and IL17A [84]. On the
other hand, it has recently been shown, that an
increased histone H3 lysine 27 trimethylation
enrichment at the hematopoietic progenitor
kinase 1 (HPK1) promoter of SLE CD4? T cells
(relative to controls) inhibits the HPK1
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expression and contributes to autoimmunity in
SLE [86]. All these reports support a role for
epigenetic DNA alterations in the pathogenesis
of SLE.
However, DNA methylation is not a process
whose effects are restricted to the DNA. As the
methylation of DNA maintains chromatin in a
condensed and hence, more inactive
configuration, it acts synergistically or
antagonistically on the diverse modifications
of histone proteins [87]. For instance,
hypomethylated CpG island chromatin is
enriched in hyperacetylated histones and
deficient in linker histones [88]. DNA
methylation may also protect individuals from
autoimmune diseases, such as SLE: as the
estrogen receptor becomes hypermethylated
during aging [89], this change may reduce the
risk for women to come down with SLE or other
sex-related autoimmune diseases. The
identification of further genes that are
deregulated by DNA (de-)methylation will
successively account for a better
understanding of the aberrant physiological
pathways of SLE.
CD4? lymphocytes undergo global histone
H3 and H4 deacetylation and consequent
skewed gene expression [68]. However,
currently little is known about the relationship
between alterations of histone modification
patterns and SLE. However, histone H3 and H4
hypoacetylation as well as a lysine 9 on H3
(H3K9) hypomethylation have been described
for SLE-derived CD4? cells [90]. The same group
observed increased histone H3 acetylation and
dimethylated H3 lysine 4 (H3K4me2) levels in
the TNFSF7 (CD70) gene promoter region in SLE
CD4? T cells, which correlated positively with
disease activity [91]. Histone acetylation is
regulated by histone acetyltransferases (HATs)
and HDACs [92, 93]. Previous studies have
shown that HDAC2 and HDAC7 levels are
downregulated in active lupus erythematosus
CD4? T cells [90] and HDAC7 is decreased in
MRL-lpr/lpr mice [94]. Moreover, it could be
shown that the specific class I and II HDAC
inhibitor ITF2357 was able to ameliorate SLE-
like symptoms in NZB/W mice through
regulation of T cell profiles [95].
Further evidence for a substantial role of
histone modification in SLE pathogenesis
comes from Lu and coworkers. They found
that the transcription factor regulatory factor
X-box 1 (RFX1) regulates CD70 and CD11a
expression in T cells of patients with SLE by
recruiting histone methyltransferase SUV39H1
[96]. The downregulation of RFX1 contributes
to DNA hypomethylation and histone H3
hyperacetylation at the CD11a and CD70
promoters in CD4? T cells of patients with
SLE, which trigger immune responses [66].
A recent study detected a correlation
between the 5-hydroxymethylcytosine (5-
hmC) level in the peripheral blood and SLE
[97]. The oxidation of 5-methylcytosine (5-mC)
to 5-hmC is an epigenetic mechanism which is
present in the DNA of mammalian cells. First
seen in bacteriophages in 1952 [98], it was then
found in high levels in neurons of the central
nervous system in human and mouse as well as
in embryonic stem cells [99, 100]. The exact
function of this sixth DNA base is not fully
understood, but it is thought to regulate gene
expression and prompt DNA demethylation.
This hypothesis is supported by the observation
that hydroxylation of 5-mC to 5-hmC by TET1
actively promotes DNA demethylation [101].
Reduction of hmC levels in DNA is also a
hallmark of cancers and, contrary to DNA
methylation, which occurs immediately during
replication, hmC forms slowly during the first
30 h following DNA synthesis [102].
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ROLE OF MICRO RNA IN SLE
PATHOGENESIS
Micro RNA (miRNA) was initially discovered in
1993 [103] but little attention was given to these
small RNAs until 2001 [104–108]. miRNAs are an
important class of endogenous regulatory small
RNAs [109, 110] which (amongst others)
regulate the expression of genes involved in
immune activation [111]. For cancer, it has been
demonstrated that the miR-29 family induces
DNA hypomethylation by directly targeting
DNA methyltransferases thereby leading to a
re-expression of hypermethylated silenced
tumor suppressor genes [112, 113]. These
studies have shown that miRNAs are involved
in disease pathogenesis by targeting DNA
methylation. miRNAs are also implicated in
the pathology of SLE [114, 115]. One of these
miRNAs, miR-146a, is a negative regulator of the
IFN pathway. Underexpression of miR-146a
contributes to alterations in the type I IFN
pathway in lupus patients by targeting the key
signaling proteins [114]. Dai et al. [116]
identified several miRNAs that are differentially
expressed in the peripheral blood mononuclear
cells of SLE patients whose expression profiling
may provide a useful clue for the etiology of SLE.
Expression of miR-21 and miR-148a is highly
upregulated in CD4? T cells from both patients
with SLE and MRL/lpr mice [117]. These two
miRNAs promote CD4? T cell hypomethylation
by repressing DNA (cytosine-5)-
methyltransferase 1 (DNMT1) expression and
inducing the expression of autoimmune-
associated methylation-sensitive genes [117].
Another miRNA that is upregulated in CD4? T
cells from SLE patients is miR-126 [118]. The
overexpression of miR-126 in CD4? T cells from
healthy donors caused demethylation and
upregulation of the genes ITGAL (encoding
CD11a) and CD70, thereby causing T cell and
B cell hyperactivity. It could also be shown that
the expression of the mir-126 host gene EGFL7
was upregulated in CD4? T cells from patients
with SLE and that the degree of overexpression is
associated with the hypomethylation of its
promoter [119]. CCL5 (RANTES) is a
chemokine expressed by circulating T cells
which recruits leukocytes to sites of
inflammation. It could be shown that serum
levels of RANTES were significantly elevated in
patients with SLE when compared with normal
controls [120]. miR-125a negatively regulates
RANTES expression by targeting KLF13 in
activated T cells [121]. Thus, underexpression
of miR-125a contributes to the elevated
expression of RANTES in SLE. Tissue factor (TF)
is the main initiator of the blood coagulation
cascade and it could be shown that monocytes
of patients with SLE are characterized by a high
TF expression and low miR-19b and -20a levels
[122]. Reporter assays demonstrated that miR-
20a binds to TF mRNA [123]. Thus,
downregulation of miR-19b and miR-20a could
contribute to increased TF expression provoking
the hypercoagulable state characteristic of
patients with SLE. Further miRNAs involved in
SLE are miRNA-3148 [124], miRNA-1246 [125],
and miRNA-let7A [126], respectively. Excessive
activation of the innate immune system
involving toll-like receptor 7 (TLR7) has been
recognized as an important pathogenic
mechanism in SLE [127] and miR-3148, with a
predicted binding site at the 30-untranslated
region (30-UTR) of TLR7 mRNA, modulates the
allelic expression of this gene. Individuals
carrying the G allele of the single nucleotide
polymorphism (SNP) rs3853839 in the 30-UTR of
the TLR7 gene exhibited increased TLR7
expression at both the mRNA and protein level
and decreased transcript degradation [124]. In
contrast, in people bearing the non-risk C allele
of this SNP, miR-3148 perfectly matches the 30-
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UTR of the TLR7-mRNA, leading to a faster and
more effective degradation of non-risk allele
containing TLR7 transcripts. For miR-1246, it
was shown that its expression was significantly
decreased in B cells from SLE patients and that it
specifically targeted the 30-UTR of the early B cell
factor 1 (EBF1) mRNA [125]. These findings
provide a causal role of miR-1246 in the
pathogenesis of SLE: EBF1 contributes to the
development, activation, and proliferation of B
cells through activation of the AKT signaling
pathway. A downregulation of the miR-1246
expression may decrease the degradation rate of
the EBF1 mRNA, leading to a B cell
overactivation in patients with SLE. Let-7a is
implicated in SLE pathogenesis due to its
responsiveness to immune stimulation and its
reported inflammatory targets [128, 129]. It
could be shown that its overexpression may
contribute to hyperplasia and a
proinflammatory response, including
inflammatory mediator production. Recent
studies have shown that a significant fraction
of miRNAs themselves is regulated by epigenetic
mechanisms [130–132], demonstrating the
entire complexity of eukaryotic gene regulation.
We now know that changes in DNA
methylation, mRNA, and miRNA expression
are characteristic for SLE and correlate with
the phenotype of this severe disease [133].
However, more studies are required to
consolidate the role of miRNAs in SLE
pathology. Until then, the question of if these
non-coding RNAs are ‘‘hope or hype’’ [134]
remains unanswered for SLE.
CONCLUSION
Deciphering the contribution of epigenetic
alterations to the pathogenesis of SLE will
provide promising insights in this complex
autoimmune disease. Epigenetic alterations are
(potentially) reversible and hence candidates for
the development of new therapeutics. However,
to attain this goal, many questions remain to be
answered in the promising field of epigenetics.
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